Literature DB >> 11549549

Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats.

H Nunes1, D Lebrec, M Mazmanian, F Capron, J Heller, K A Tazi, E Zerbib, E Dulmet, R Moreau, A T Dinh-Xuan, G Simonneau, P Hervé.   

Abstract

The hepatopulmonary syndrome (HPS) is characterized by intrapulmonary vascular dilatations and an increased alveolar-arterial oxygen difference (AaPO(2)). Exhaled nitric oxide (NO) concentrations are elevated, suggesting that pulmonary NO overproduction may be the mechanism underlying HPS. We investigated whether common bile duct ligation in rats results in lung NO overproduction and whether normalization of NO synthesis by a 6-wk course of N(G)-nitro-L-arginine methyl ester (L-NAME) (5 mg x kg(-)(1) x d(-)(1)) prevents HPS. Untreated cirrhotic rats showed increases in AaPO(2) and in cerebral uptake of intravenous (99m)Tc-labeled albumin macroaggregates (indicating intrapulmonary vascular dilatations), with decreases in pulmonary vascular resistance and in pulmonary vasoconstriction induced by angiotensin II and hypoxia. Increases were found in exhaled NO; pulmonary total and calcium-dependent NO synthase (NOS) activities; and pulmonary expression of inducible and, to a lesser extent, endothelial NOS. Accumulation of intravascular macrophages accounted for the inducible NOS expression. L-NAME normalized AaPO(2), brain radioactivity, pulmonary vascular resistance, reactivity to hypoxia and angiotensin II, exhaled NO, and NOS activities. These findings suggest that HPS and the associated reduced response to pulmonary vasoconstrictors seen in untreated cirrhotic rats are related to increased pulmonary NO production dependent primarily on increases in the expression and activities of inducible NOS within pulmonary intravascular macrophages.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549549     DOI: 10.1164/ajrccm.164.5.2009008

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  33 in total

1.  Smoking and Liver Disease.

Authors:  Stephanie M Rutledge; Amon Asgharpour
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-12

Review 2.  [Pulmonary complications in liver diseases].

Authors:  T Horvatits; A Drolz; K Rutter; S Kluge; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-26       Impact factor: 0.840

3.  Arterial hypoxemia and intrapulmonary vasodilatation in rat models of portal hypertension.

Authors:  Yasumi Katsuta; Xue-Jun Zhang; Masaru Ohsuga; Toshio Akimoto; Hirokazu Komeichi; Shuji Shimizu; Yoshihito Kato; Akiko Miyamoto; Katsuaki Satomura; Teruo Takano
Journal:  J Gastroenterol       Date:  2005-08       Impact factor: 7.527

Review 4.  Hepatopulmonary Syndrome.

Authors:  Yong Lv; Daiming Fan
Journal:  Dig Dis Sci       Date:  2015-03-03       Impact factor: 3.199

Review 5.  Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.

Authors:  Sarah Raevens; Michael B Fallon
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

6.  Pilot study of pentoxifylline in hepatopulmonary syndrome.

Authors:  Rajasekhar Tanikella; George M Philips; Dorothy K Faulk; Steven M Kawut; Michael B Fallon
Journal:  Liver Transpl       Date:  2008-08       Impact factor: 5.799

7.  Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome.

Authors:  Junlan Zhang; Bao Luo; Liping Tang; Yongming Wang; Cecil R Stockard; Inga Kadish; Thomas Van Groen; William E Grizzle; Selvarangan Ponnazhagan; Michael B Fallon
Journal:  Gastroenterology       Date:  2008-12-03       Impact factor: 22.682

8.  Exhaled nitric oxide measurement to monitor pulmonary hypertension in a pneumonectomy-monocrotaline rat model.

Authors:  Magdalena Strobl; Catharina Schreiber; Adelheid Panzenböck; Max-Paul Winter; Helga Bergmeister; Johannes Jakowitsch; Julia Mascherbauer; Irene M Lang; Paul Wexberg; Diana Bonderman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-07-26       Impact factor: 5.464

9.  Sarcoidosis complicated by cirrhosis and hepatopulmonary syndrome.

Authors:  Samir Gupta; Marie E Faughnan; Gerald J Prud'homme; David M Hwang; David G Munoz; Peter Kopplin
Journal:  Can Respir J       Date:  2008-04       Impact factor: 2.409

10.  Alveolar exhaled nitric oxide is elevated in hereditary hemorrhagic telangiectasia.

Authors:  Samir Gupta; Noe Zamel; Marie E Faughnan
Journal:  Lung       Date:  2008-10-24       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.